Automated Surveillance, Alert, & Rapid Diagnosis of Thrombotic

Status Not yet recruiting

Clinical Trial Summary

Recently a pilot study was conducted to evaluate the impact of an electronic alert (e-alert) triggered by the automated algorithm in the efficiency and rapidity in TMA patients' identification in our University Hospital A. Gemelli over 12 months.the TMA diagnostic algorithm has been implemented in the laboratory software of the hospital and applied whenever a patient in the Emergency ward or any other department undergoes blood tests that include platelet count and lactate dehydrogenase. The basic profile in the Emergency ward always has these two parameters. The algorithm automatically identifies patients with a predicted probability of TMA >90% (6); if this criterion is associated with a platelet count<100 x 109/L, an automated warning to the hematologist on-call is issued with an SMS, and the patient enters the TMA diagnostic process defined in the diagnostic and treatment pathways (Percorso Diagnostico e Terapeutico Assistensiale, PDTA). The on-duty hematologist urgently evaluates the patient for whom a warning has been issued, relating with the clinician(s) of the ward in which the patient is located. If the suspicion of TMA is confirmed, the diagnostic procedures outlined in the PDTA are performed, with the immediate execution of 2nd level tests. If the on-duty hematologist considers the diagnosis of aHUS possible, they contact the on-call Nephrologist directly for immediate diagnostic investigation and specific urgent therapeutic measures, as needed. The TMA-expert Hematologist and/or TMA-expert Nephrologist is notified as soon as possible by the on-duty hematologist of all cases, both highly suspected and uncertain, and follow up all patients to complete the diagnostic workup to confirm or rule out the diagnosis and implement the appropriate clinical measures. Therefore, the treatment in smaller hospitals that do not have a 24-hour hematological guard service available and the same awareness for TMA. The present study aims to validate these results by testing the system in a multicenter study involving centers with different availability of the hematologist and awareness for TMA.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05996679
Study type	Observational
Source	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact
Status	Not yet recruiting
Phase
Start date	October 1, 2023
Completion date	October 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04098445` - TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Completed	`NCT02222545` - Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies	Phase 2
Recruiting	`NCT06102694` - Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
Completed	`NCT03252925` - A Safety and Efficacy Study of NAC in Patients With TA-TMA	Phase 3
Not yet recruiting	`NCT06182410` - Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma	Phase 2
Recruiting	`NCT05855083` - Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA	Phase 2
Completed	`NCT03384693` - Defibrotide TMA Prophylaxis Pilot Trial	Phase 2
Not yet recruiting	`NCT05702996` - Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies	Phase 3
Not yet recruiting	`NCT02373267` - Screening of TMA Patients für ADAMTS13 Activity (Adamscreen)	N/A
Recruiting	`NCT06098378` - Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab
Completed	`NCT02134171` - Early Predictive Factors of Cardiac and Cerebral Involvement in TMA	N/A
Withdrawn	`NCT04970004` - Study in Adult and Pediatric Patients With HSCT-TMA
Recruiting	`NCT03205995` - Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome	Phase 3
Recruiting	`NCT04784455` - Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy	Phase 3
Active, not recruiting	`NCT04570397` - Ravulizumab and COVID-19	Phase 3
Recruiting	`NCT05634928` - Construction of a Database for TMA
Completed	`NCT03518203` - Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients	Phase 2
Recruiting	`NCT04745195` - Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
Recruiting	`NCT06291415` - The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA Study — ASARD-TMA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms